Caring Cross press release
Caring Cross announced early clinical data from a first-in-human Phase I/IIa trial of a novel CAR-T cell strategy in people living with HIV.
The findings provide preliminary data suggesting that anti-HIV CAR-T cell therapy could lead to durable viral control, particularly in those who started HIV treatment early in the course of their infection.
The Phase I/IIa clinical trial is evaluating the safety and preliminary efficacy of an anti-HIV duoCAR-T therapy in ART-suppressed individuals. The therapy uses a participant’s own T cells, which are genetically engineered using Caring Cross’s proprietary duoCAR technology and reinfused. To date, nine participants have received therapy in this first-in-human dose-escalation study.
Read the full press release here.
Source : Caring Cross
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.